French pharmaceutical group Servier has announced its definitive agreement to acquire Day One Biopharmaceuticals for approximately $2.5 billion in cash. This strategic move significantly expands Servier’s oncology portfolio, particularly in rare cancers, and strengthens its pipeline with targeted therapies for both adult and pediatric patients with high unmet medical needs.
The acquisition positions Servier as a leader in pediatric low-grade glioma (pLGG), a common childhood brain tumor. Day One’s flagship product, Ojemda (tovorafenib), a type 2 RAF inhibitor approved by the FDA in April 2024, targets relapsed or refractory pLGG in patients six months and older. This drug is expected to complement Servier’s existing oncology offerings, including Voranigo, acquired in 2021.
Beyond Ojemda, Servier will gain access to Day One’s early- to late-stage pipeline. This includes further development programs for tovorafenib in pLGG and other assets targeting indications such as adenoid cystic carcinoma and various adult and pediatric solid tumors. The combination of Day One’s scientific expertise and Servier’s global capabilities aims to accelerate the delivery of innovative treatments.
Servier will commence a cash tender offer to acquire all outstanding shares of Day One common stock at $21.50 per share. This price represents a premium of approximately 68% over Day One’s closing price on March 5, 2026. The transaction is subject to customary closing conditions, including shareholder tender of a majority of shares and U.S. antitrust clearance. Servier plans to fund the acquisition through existing cash and investments. Goldman Sachs Bank Europe SE advised Servier, while Centerview Partners LLC advised Day One.
Olivier Laureau, President of Servier, stated that the acquisition is a decisive step in strengthening the company’s position in rare oncology and aligns with its 2030 ambition to develop innovative treatments for patients with high unmet medical needs. Day One’s CEO, Jeremy Bender, Ph.D., expressed confidence that Servier’s track record in rare cancers makes it an ideal partner to extend the reach of their science and maintain a patient-first mindset.